Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood. High diagnostic accuracy : Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI. Convenience : No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling Efficiency: Provides diagnosis opportunities to more people in situations where personnel and devices are limited
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
PC-PASS Protein Characterization Analysis Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
Airborne virus sterilization rate: 88.2% Virus proximity (30Cm) distance sterilization: 100% Ozone generation: None detected UV : No occurrence Fine dust removal rate: 91.3% CADR (Clean Air Purification Capacity): 36m³/h Radon removal rate: more than 97% Applied area is 5 square meters. (Use one per 3.3 square meters in places where people are clustered, such as schools and cafes.) *Installation Case* Meat processing plant, Elevators, School, Coffee Shop, Kindergarden, Restaurant *If it is in the form of a socket, it can be replaced immediately without installation. *If it is not a socket type, the rail must be installed on the ceiling.
Support food Crispy and testy 13g high-protein bar * Recommended intake and how to intake Intake from time to time when you want refreshment * Key point High protein High protein Whole nuts * Recommend to those who Want simple breakfast Supplement protein shortage through diet control Want high protein intake easily Are sick and tired of poor taste protein powder for diet Are worried about frequent refreshment habit Delicious protein
Support food Daily cleansing to empty body * Recommended intake and how to intake Intake more than 1 time per day. Intake by mixing 110g per time with water (250~300mL) * Key point Vitamin C Delicious cleanse Daily cleanse Improvement of intestine environment * Recommend to those who Are tired of repetitive nightwork Feel heavy due to frequent get-together Are tired due to bad diet habit Seek easy intake cleanse product Seek sugar-free, pigment-free, preservative-free and
Beauty , inner beauty Skin and daily vitality at once #Skin recovery agent * Premium place of origin Norwegian small molecule fish Collagen 1,000mg * 4 major ingredients Optimal formula that incorporates skin composition and all four elements * Improves skin vitality with taurine 500mg for fatigue recovery * Contains carefully selected 9 vitamins complex and premium subsidiary ingredients
LAYER 4Layer (FLEXIBLE 2L+RIGID 4L) 4-2-4-3-2 Application Blood Sugar Check Thickness 0.38T Structure 2-3L DRILL, 1-2L, 3-4L BLIND VIA Machine Drill Min. 0.1mm Laser Drill BVH Min. 0.1mmSTACK VIA FILL copper plating Cu Plating INNER : VIA FILL / OUT : PTH Min.20+ VIA FILL L/S 50 / 50 (SPECIAL) PSR GREEN Surface treatment ENIG Stiffner PI (3Mil) Impedance 100
Board MAIN, MP3, MOTOR, LAMP, 3P, 9P PBA
We have constantly put our entire effort to develop treatment medical supplies to take a part in national health improvement.
We have constantly put our entire effort to develop treatment medical supplies to take a part in national health improvement.
We have constantly put our entire effort to develop treatment medical supplies to take a part in national health improvement.
We have constantly put our entire effort to develop treatment medical supplies to take a part in national health improvement.
We have constantly put our entire effort to develop treatment medical supplies to take a part in national health improvement.
We have constantly put our entire effort to develop treatment medical supplies to take a part in national health improvement.
We have constantly put our entire effort to develop treatment medical supplies to take a part in national health improvement.
